Physician profile
James Connor
NPI 1245250919
$1,687.90
in general payments reported to CMS, 2019-2025
24 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.13 · 2020: $74.99 · 2021: $102 · 2022: $252 · 2023: $227 · 2024: $394 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $405.57 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $300.17 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $255.30 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Exact Sciences Corporation | $132.40 | 2023-2025 | Cologuard Collection Kit |
| Abiomed | $78.86 | 2025 | |
| Amgen INC. | $70.68 | 2022-2024 | Repatha, Otezla |
| Abbott Laboratories | $70.36 | 2022-2024 | Freestyle Libre 3 |
| Alnylam Pharmaceuticals INC. | $52.32 | 2024 | Givlaari |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.67 | 2023-2025 | Xifaxan |
| Ucb, INC. | $32.15 | 2025 | Bimzelx |
| Janssen Pharmaceuticals, INC | $26.21 | 2020-2021 | |
| Astellas Pharma US INC | $24.64 | 2025 | Veozah |
| Boston Scientific Corporation | $23.80 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.52 | 2025 | Caplyta |
| Axonics, INC. | $17.79 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.52 | 2022 | |
| Medtronic, INC. | $16.70 | 2025 | Inceptiv |
| Janssen Biotech, INC. | $16.70 | 2023 | Stelara, Simponi, Remicade |
| Dexcom, INC. | $16.66 | 2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $15.86 | 2019 | |
| Sun Pharmaceutical Industries INC. | $15.45 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.12 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $14.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.